<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Mutation analysis of KRAS is needed before starting treatment with anti-EGFR monoclonal antibodies in patients with <z:e sem="disease" ids="C0948380" disease_type="Neoplastic Process" abbrv="">metastatic colorectal cancer</z:e> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRC</z:e>) </plain></SENT>
<SENT sid="1" pm="."><plain>In most of the cases, testing is performed on <z:e sem="disease" ids="C0677930" disease_type="Neoplastic Process" abbrv="">primary tumors</z:e>, assuming that KRAS mutation status does not change in <z:e sem="disease" ids="C0027627" disease_type="Neoplastic Process" abbrv="mets">metastasis</z:e> although correlation studies gave conflicting results </plain></SENT>
<SENT sid="2" pm="."><plain>We evaluated the KRAS status concordance rate between <z:e sem="disease" ids="C0677930" disease_type="Neoplastic Process" abbrv="">primary tumors</z:e> and related <z:e sem="disease" ids="C0027627" disease_type="Neoplastic Process" abbrv="mets">metastasis</z:e> using a highly sensitive molecular assay </plain></SENT>
<SENT sid="3" pm="."><plain>Forty-five <z:e sem="disease" ids="C0677930" disease_type="Neoplastic Process" abbrv="">primary tumors</z:e> and related <z:e sem="disease" ids="C0027627" disease_type="Neoplastic Process" abbrv="mets">metastases</z:e> from patients with <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRC</z:e> (28/45 male-62.2% and 17/45 female-37.8%; mean age 66.4 years) were analyzed by using TheraScreen: KRAS mutational kit </plain></SENT>
<SENT sid="4" pm="."><plain>Metastatic samples were collected from lymph nodes (8/45-17.8%) and visceral sites (37/45-82.2%); 23 were synchronous (49%) and 22 were metachronous (51%), obtained after a mean of 30.8 months after the first diagnosis of <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRC</z:e> </plain></SENT>
<SENT sid="5" pm="."><plain>Twenty-eight patients had KRAS mutations in both primary <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRC</z:e> and related <z:e sem="disease" ids="C0027627" disease_type="Neoplastic Process" abbrv="mets">metastases</z:e> (62.2%) </plain></SENT>
<SENT sid="6" pm="."><plain>No differences in type and frequency of mutations were identified, despite different metastatic sites and time of <z:hpo ids='HP_0003674'>onset</z:hpo> of <z:e sem="disease" ids="C0027627" disease_type="Neoplastic Process" abbrv="mets">metastatic disease</z:e> </plain></SENT>
<SENT sid="7" pm="."><plain>Our results indicate that the mutation status of KRAS is the same in primary <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRC</z:e> and <z:e sem="disease" ids="C0027627" disease_type="Neoplastic Process" abbrv="mets">metastasis</z:e>, suggesting that in clinical practice, KRAS testing can be performed on both <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> tissues when using a highly sensitive molecular assay </plain></SENT>
</text></document>